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INTRODUCTION
Varicella-zoster virus (VZV), a herpesvirus, consists of a
double-stranded DNA genome surrounded by a pro t e i n
tegument and contained within an icosahedral capsid and an
outer lipid membrane envelope [1,2]. The VZV genome has
69 distinct genes that encode proteins re q u i red for viru s
attachment and entry into host cells, replication of viral
DNA, and synthesis of new virions and their release or
spread to adjacent uninfected cells (Figure 1). 
V Z V, like other human herpesviruses, is a threat to
hematopoietic cell transplantation (HCT) recipients [3,4].
During primary infection, which causes varicella, VZV
establishes latency in cells of the dorsal root sensory ganglia.
Among adult HCT patients, most VZV infections represent
a reactivation of the latent virus. Classic herpes zoster, with
its dermatomal vesicular rash, is the most common clinical
s y n d rome caused by VZV reactivation, but some HCT
recipients have a generalized vesicular exanthema that
resembles varicella, syndromes of neuropathic pain, or
organ involvement that is not associated with any rash. 
BIOLOGY OF VZV LATENCY AND REACTIVATION
New information about the mechanisms of VZV patho-
genesis helps to explain the risks associated with VZV re a c-
tivation in HCT recipients. The pathogenesis of VZV
infection involves 3 essential cellular tropisms: infectivity
for epithelial cells of the mucous membranes and skin, for
c i rculating peripheral blood mononuclear cells, and for
cells of the sensory ganglia. 
VZV Infectivity for T Cells and Skin
In addition to causing characteristic skin lesions, VZV
can be detected in peripheral blood mononuclear cells
f rom healthy and immunocompromised patients with vari-
cella and from immunodeficient patients with herpes
z o s t e r. Using the SCID-hu mouse model, we have demon-
strated that VZV infects CD4+ and CD8+ human T cells
and thus shares pathogenic mechanisms characteristic of
the lymphotropic and n e u ro t ropic herpesviruses (Figure
2) [5,6]. Infectivity for T cells is a critical component of
the risk that VZV presents in HCT recipients, since it
underlies susceptibility to cutaneous and visceral dissemi-
nation. Conditions in the SCID-hu model are similar to
those in the period immediately after HCT, since SCID-
hu mice lack the capacity to develop VZV-specific immu-
n i t y. When VZV reactivates in the human host, it re p l i-
cates efficiently in the skin,  producing high titers of
infectious virus in the cutaneous vesicles. During acute
herpes zoster, T cells may become infected at the site of
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local cutaneous replication or may acquire virus fro m
actively infected cells within the affected ganglia [7]. If the
host response is impaired, T cells can transport the virus to
lungs, liver, brain, and other org a n s .
VZV infectivity for human T cells as well as skin is
re q u i red for pathogenesis, but our comparative analyses
of VZV mutant strains that have altered expression of
p a rticular viral genes demonstrate that these tropisms are
mediated by different viral proteins, termed virulence deter-
minants. VZV strains that lack glycoprotein C (gC) expres-
sion have little or no capacity to replicate in skin. In con-
trast, gC synthesis is not required for T-cell infection. Thus,
gC is a specific determinant for VZV virulence in skin [6].
In addition to the contribution of glycoproteins to VZV
pathogenesis, gene products that have no putative or
demonstrated role in viral entry into human cells have
e m e rged as key determinants of VZV virulence. The pro-
teins encoded by the open reading frames (ORFs) 47 and
66 a re serine/threonine protein kinases [2]. We used VZV
mutants that were constructed to block expression of
ORF47 to demonstrate that this protein is essential for viral
g rowth in human T cells and skin [8]. Absence of ORF66
expression partially inhibited VZV infectivity for T cells but
did not impair replication in skin relative to the intact virus.
Infectivity for T cells and skin was re s t o red when the
mutant was re p a i red by inserting intact ORF47 back into
the genome. The ORF47 gene product is the first VZV pro-
tein to be identified as necessary for T-cell tropism. Like
gC, ORF47 is also essential for skin infectivity in vivo. 
Among the human herpesviruses, VZV is related most
closely to herpes simplex virus (HSV). The comparison of
VZV and HSV-1 infection in the SCID-hu model revealed
significant differences in T-cell and skin tropisms that corre-
late with the clinical experience of pathologic effects in
HCT recipients and other immunocompromised individuals
[6]. VZV caused extensive necrosis in deeper dermal layers
of skin implants, whereas HSV-1 was confined to the epi-
d e rmis. In contrast to VZV, HSV-1 was not infectious for
human CD4+ or CD8+ T cells, which is consistent with the
clinical observation that HSV infection is rarely associated
with viremia, even in high-risk patients. 
Classic herpes zoster results from transport of the viru s
along neuronal axons from the cellular sites of latency in dor-
sal root ganglia. However, disseminated VZV infection has
been diagnosed at autopsy in HCT patients without cuta-
neous lesions [3]. This clinical syndrome suggests that the
v i rus can enter T cells when they traffic through dorsal ro o t
ganglia during VZV reactivation. Our studies using poly-
merase chain reaction (PCR) to detect the virus in peripheral
blood mononuclear cells (PBMC) demonstrate that this event
is not unusual in HCT patients, especially during the fir s t
100 days after transplantation (Figure 3) [9]. Activated T cells
a re more permissive for VZV infection in vitro, so HCT
patients may be more likely to develop cell-associated infec-
tion because activated T cells persist in circulation for a pro-
longed interval after transplant [10-12]. The evaluation of
HCT recipients by VZV PCR assay demonstrated that VZV
reactivation can occur without cutaneous lesions and that
many patients resolve reactivation and viremia without devel-
oping signs of visceral dissemination [9]. 
N e u ro t r opism of VZV
The hypothesis that herpes zoster results from the re a c-
tivation of latent virus acquired during varicella was pro v e n
by restriction enzyme analysis showing that a single VZV
strain caused both varicella and subsequent herpes zoster in
an immunocompromised child [13]. During varicella, VZV is
postulated to move up neuronal axons from skin lesions to
the corresponding sensory ganglia. Immunohistochemical
stains of skin lesions demonstrate the presence of VZV pro-
teins in nerve termini, axons, and Schwann cells [14]. In our
animal model experiments, subcutaneous inoculation of
guinea pigs with VZV was associated with spread of virus to
s e n s o ry ganglia [15]. Vi remia may also carry VZV to gang l i o n
cells, as suggested by VZV spread to ganglia in neonatal rats
inoculated intraperitoneally [16]. After earlier conflicting
re p o rts, recent experiments done with more sensitive and
specific methods indicate that VZV establishes latency in
Figure 1. Diagram of varicella-zoster virus (VZV) and viral proteins in VZV-infected cells. 
VZV After HCT
221B B & M T
Figure 2. Varicella-zoster virus (VZV) infection of T cells and skin in the SCID-hu model. A: Infected T cells within a thymus/liver implant after inoculation
with VZV. a: Macrophages engulf infected T cells. b: Day 7, lymphocyte depletion. c: Day 21, complete destruction. d: Mock-infected control. B: Virus-induced
changes in an infected skin implant. a: Infected cells in epidermis and around hair follicles. b: Vesicular lesion involving dermis. c: Mock-infected control. 
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n e u ronal as well as satellite cells within dorsal root ganglia
[17-20]. How virus/cell interactions result in the mainte-
nance of latency remains uncertain, but these mechanisms
must differ for VZV and HSV. VZV latency is associated
with the expression of several viral gene products, in contrast
to HSV, in which only antisense latency-associated tran-
scripts are detected. Transcripts of ORFs 21, 29, 62, and 63
have been detected, and there is evidence that proteins of
ORFs 4, 21, 29, and 62 are made in latently infected cells
[17,21]. VZV, like HSV, is presumed to persist in latently
infected cells as an episome, rather than by integration into
cellular DNA [22]; persistence must occur without transla-
tion of the full sequence of viral gene products, because
virion production would be expected to be associated with
cell lysis. Although the assessment of viral load in ganglia is
d i fficult, quantitative DNA PCR analysis of human trigemi-
nal ganglia suggests the presence of about 250 VZV genome
equivalents per 105 cells [23]. The estimates of virus burd e n
suggest that VZV persists in more cells of the trigeminal
than thoracic ganglia, which could explain the re l a t i v e l y
higher incidence of facial zoster. When reactivation occurs,
extensive viral replication takes place within the cells of the
s e n s o ry ganglia, producing pathologic changes including
extensive inflammation and necrosis [24]. The virus moves to
the skin innervated by the involved ganglion via axonal trans-
p o rt, causing the dermatomal rash of typical herpes zoster.
IMMUNE EVASION AND THE HOST RESPONSE 
TO VZV INFECTION
Whether the host response contributes directly to pre-
s e rving VZV latency at the cellular level is not known. Neu-
rons or satellite cells that harbor VZV are assumed to re m a i n
invisible to the immune system during latency, or adverse
consequences would result from the cumulative destru c t i o n
of neuronal cells. Nevertheless, the high incidence of herpes
zoster in HCT recipients who are latently infected because of
childhood varicella and lose antigen-specific immunity during
HCT provides compelling evidence that immunologic mech-
anisms modulate the frequency of symptomatic episodes of
VZV reactivation. Under ord i n a ry circumstances, h e r p e s
zoster re p resents a useful strategy of the virus, ensuring its
persistence in the human population. Cutaneous re c u rre n c e s
give VZV an opportunity for transmission to susceptible close
contacts while causing only a self-limited skin rash with some
n e u ropathic pain, which is uncomfortable but not life-thre a t-
ening to the healthy individual. Herpes zoster infection
reveals the limitations of immune surveillance even in the
immunocompetent host, since it occurs despite circ u l a t i n g
V Z V- s p e c i fic memory T cells. To evade established immu-
n i t y, replicate in skin cells, and release infectious virus into
vesicular fluid, VZV virus, it is thought, has evolved ways to
avoid antigen-specific T-cell re s p o n s e s .
I m m une Evasion
Like other herpesviruses, VZV encodes gene pro d u c t s
that downregulate major histocompatibility complex
(MHC) class I expression on fibroblasts and T cells (A.
A b e n d roth,  I. Lin, A.M.A., unpublished data) [25].
Restricted class I expression interf e res with recognition of
VZV-infected cells by CD8+ T cells. Although the viral pro-
tein or proteins that mediate class I downregulation have
not been identified, we found that MHC class I molecules
exit from the endoplasmic reticulum (ER) but are retained
in the Golgi (A. Abendroth, I. Lin, A.M.A., unpublished
data). In contrast, HSV blocks transport of class I proteins
from the ER by effects of ICP47, the product of a gene that
is not found in the VZV genome [26]. Because MHC class I
molecules are expressed on almost all mammalian cells and
function to present foreign peptides to CD8+ T cells, inter-
ference with their transport to the cell surface makes VZV-
infected cells more difficult to eliminate by this arm of the
antiviral immune response. 
In addition to limiting MHC class I trafficking to the
cell surface, VZV-infected cells are resistant to the upregu-
lation of MHC class II expression elicited by interf e ro n
( I F N ) -γ [27]. MHC class II molecules present peptides to
s u p p o rt the clonal expansion of CD4+ T cells. With the
exception of B cells, monocytes, and thymic epithelium,
most cells do not express MHC class II proteins constitu-
tively, but exposure to IFN-γ triggers rapid upregulation of
these proteins on membranes of many cell types. VZV- s p ecific
m e m o ry CD4+ T cells are programmed to synthesize and
release IFN-γ when stimulated by viral antigen [7]. Our
analysis of VZV effects on this pathway revealed that the
block of IFN-γ–induced MHC class II expression occurred
at the level of gene transcription within the infected cell
( F i g u re 4). Examination of skin biopsies taken from early
herpes zoster lesions demonstrated that VZV-infected cells
did not express MHC class II in vivo, suggesting a mecha-
nism that transiently protects VZV-infected cells despite cir-
culating VZV memory CD4+ T cells. This effect is transient
most likely because synthesis and transport of MHC class II
molecules to the cell surface are normal when uninfected
cells are exposed to IFN-γ. As herpes zoster progresses, the
re c ruitment of VZV-specific CD4+ T cells that pro d u c e
IFN-γ to the cutaneous site of VZV replication should con-
t rol the cell-to-cell spread of the virus. Even if the viru s
enters adjacent uninfected cells, IFN-γ released by memory
C D 4+ T cells should make these secondarily infected cells
detectable by effector T cells. 
Figure 3. Detection of polymerase chain reaction product after amplification
of DNA from peripheral blood mononuclear cells. Samples from 3 bone mar-
row transplant (BMT) patients who had subclinical cell-associated viremia are
shown in 1A, 1C and 1D; samples from 5 BMT patients without detectable
VZV viremia are shown in 1B and 2C-F. Samples 1F and 2B are the VZV
DNA controls; sample 2A is PBMC from a healthy immune donor control.
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A n t i g en-Specific T-Cell Frequencies in Ada p t i v e
I m m unity to VZV
The escape of VZV from immune surveillance is associ-
ated with declining numbers of VZV-specific memory
T cells in the latently infected host [28]. Conversely, the risk
of herpes zoster is decreased when VZV-specific T- c e l l
responses are detected. Among HCT recipients and other
patients with cellular immunodeficiencies, prolonged peri-
ods of lymphopenia and the loss of VZV-specific T cells
predict an interval of high risk for VZV reactivation [3,9,29-
38]. The most severely immunocompromised patients, such
as HCT recipients, are most susceptible to herpes zoster.
Among these patients, memory T cells—which can prolifer-
ate in response to VZV antigen, make cytokines such as
I F N -γ, tumor necrosis factor (TNF)-α or interleukins, or
have cytotoxic activity against VZV-infected cells—fall
below the threshold of detection [37]. Otherwise healthy
elderly individuals have a higher risk of VZV reactivation as
a result of immunosenescence; these individuals have some
V Z V-specific T cells but lower frequencies of re s p o n d e r
T cells than younger adults. In contrast to correlation with
loss of cellular immunity, a prospective analysis of the risk of
herpes zoster and VZV antibody titers in the HCT donor or
recipient revealed no relationship [39].
Innate Host Responses to VZV
Despite the correlation between loss of VZV- s p e c i f i c
m e m o ry T cells and the risk of VZV re c u rrence, the
absence of detectable responses for prolonged periods
appears to be a necessary, but not sufficient, condition for
VZV reactivation from latency. This observation suggests
that nonspecific antiviral immunity helps to restrict the
symptoms of VZV reactivation. In contrast to virus-specific
T-cell immunity, natural killer (NK) cell activity comparable
to that of healthy subjects is recovered during the first few
months after HCT [39]. When evaluated for cytotoxicity
against VZV-infected targets, some HCT recipients had a
predominance of NK cells expressing CD16 surface antigen,
and infected cells were lysed by class I and class I–indepen-
dent mechanisms [9]. IFN-α is made by NK cells and
monocytes without requiring the presence of antigen-
specific T cells and has direct antiviral activity against VZV.
A functional role for this protein was suggested by the effi-
cacy of exogenous IFN-α in reducing the severity of recur-
rent VZV infections in immunocompromised patients when
given within 72 hours after the appearance of the cutaneous
rash [40]. Nonspecific cytotoxic responses and induction of
antiviral cytokines may function to control VZV replication
before the recovery of virus-specific T cells after HCT.
Granulysin is a newly described cytolytic protein made
by NK cells as well as by antigen-specific CD8+ T cells [41].
Our recent experiments demonstrate that granulysin
i n c reases the death rate of VZV-infected cells in vitro [42].
When VZV-infected cells were exposed to granulysin, syn-
thesis of infectious virus was reduced dramatically and death
of VZV-infected cells was accelerated. VZV infection of
f i b roblasts in the absence of granulysin caused downre g u-
lated surface expression of the cellular protein fas and inhib-
ited susceptibility of infected cells to apoptosis triggered by
anti-fas immunoglobulin M (IgM). Granulysin release by
NK cells re p resents an innate immune response that may
reverse this virus-induced block of apoptosis, resulting in cell
death before large numbers of infectious virions can be syn-
thesized. Secretion of granulysin by NK cells may enhance
the early destruction of VZV-infected cells in the absence of
m e m o ry T cells that mediate adaptive immune responses. 
RECONSTITUTION OF VZV-SPECIFIC T-CELL IMMUNITY
AFTER HCT
HCT patients have a gradual re c o v e ry of memory
T cells that recognize VZV antigens (Figure 5) (A. Hata, L.
Zerboni, M. Sommer, A.A. Kaspar, C. Clayberg e r, A.M.
K re n s k y, A.M.A., unpublished data) [7,9,30]. Detection of
VZV memory T cell s is usually  possible by 9 to 12
months after HCT and correlates with a reduction in the
Figure 4. Interference by varicella-zoster virus (VZV) with interferon (IFN)-γ–induced upregulation of major histocompatibility complex class II expression via
the Stat signal transduction pathway. Reprinted with permission [26].
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overall risk of herpes zoster and its complications. Never-
theless, the recovery of adaptive immunity to VZV may not
occur until after the patient has experienced herpes zoster.
Once VZV reactivation occurs, most HCT recipients are
effectively resensitized to the virus. In the earliest study of
the reconstitution of VZV T-cell immunity, Meyers et al.
[43] detected T-lymphocyte proliferation to VZV in 16 of
18 patients (89%) after symptomatic re c u rrences of VZV
versus 15 of 29 patients (51%) who did not develop herpes
z o s t e r. Almost half of the HCT recipients re c o v e red VZV
immunity with no clinical signs of recurrence. Thus, innate
immune mechanisms may be adequate to control viral repli-
cation while naive T cells are induced to become antigen-
specific or while the few remaining antigen-specific T cells
undergo sufficient clonal expansion. This pattern of recon-
stitution suggests that the subclinical episodes of re a c t i v a-
tion, documented by VZV PCR, may provide the stimulus
to re s t o re adaptive immunity to VZV [9]. Pre t r a n s p l a n t
immunity in both donor and recipient may also facilitate the
recovery of VZV-specific T cells [43]. 
In addition to proliferative and cytokine responses, at
later times after HCT, patients also develop cytotoxic T lym-
phocytes (CTL) that can recognize and lyse autologous tar-
get cells that express VZV proteins [9]. In our experience,
50% of HCT patients had VZV- s p e c i fic CTL function when
tested a mean of 155 days after transplant (Figure 6). How-
e v e r, the mean precursor frequency of T lymphocytes that
recognized the VZV IE62 protein or glycoprotein E (for-
merly designated gp I) was more than 2-fold lower among
HCT recipients than the frequency of CTL that re c o g n i z e d
these viral proteins in PBMC from healthy immune subjects.
In these experiments, the proliferation of CD4+ T cells was
reduced significantly compared with that of healthy subjects;
C D 8+ T cells predominated in VZV-stimulated culture s ,
re flecting the relative increase in circulating CD8+ T cells
that is common after HCT [44]. Although CD8+ T lympho-
cytes have been defined as the classic cytotoxic effector cell,
human CD4+ cells also function effectively as antiviral CTL
against many viruses, including VZV [45]. The diminished
C D 4+ T-cell response to VZV antigen may account for the
low frequencies of CTL precursors specific for the IE62 or
gE proteins in HCT recipients compared with healthy,
V Z V-immune individuals. 
Whether re c o v e ry of T cells that recognize part i c u l a r
VZV proteins affects the risk of herpes zoster is not known,
because only IE62- and gE-specific responses have been
Figure 6. Precursor frequencies of cytotoxic T lymphocytes specific for the immediate early protein (IE62) and glycoprotein I (gp I) of varicella-zoster virus in bone
marrow transplant recipients and healthy subjects. Mean ± SD for precursor frequency estimates are indicated next to the individual data points (d) generated by
testing individual hematopoietic cell transplant recipients and healthy immune subjects. Reprinted with permission [8]. 
Figure 5. Lymphocyte transformation responses of marrow transplant recipi-
ents to varicella-zoster virus (VZV) antigen. All patients and donors had a
history of VZV infection. The 9 patients who had circulating myeloblasts or
lymphoblasts before transplant are indicated by triangles (m). The 25th to
75th percentile of the normal response to VZV antigen is indicated by the
hatched area, and the horizontal lines enclose a 95% range of normal
responses. 
Time after transplantation (days)
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quantitated. In the intact host, helper and cytotoxic T- c e l l
responses specific for the IE63 protein are maintained for
decades after primary VZV infection [46]. Recovery of
responses to the immediate early proteins may be part i c u-
larly important, because these viral gene products are made
in infected cells before viral progeny are synthesized.
Recognition by the adaptive immune system could result in
lysis of infected cells at early times after virus entry, blocking
cell-to-cell spread or release of infectious virus. 
Evaluation of Inactivated Varicella Vaccine f o r
Reconstitution of VZV Imm u n i t y
Based on the evidence that natural VZV re a c t i v a t i o n
induces recovery of VZV-specific T cells, we have evaluated
whether the inactivated varicella vaccine could substitute for
the resensitization caused by VZV reactivation after HCT
and modify the incidence or severity of herpes zoster [37].
Administering the live attenuated varicella vaccine to elderly
individuals enhances VZV-specific immunity and immuniza-
tion and is being evaluated as a strategy to reverse immuno-
senescence in this population [37]. Heat inactivation of the
live attenuated varicella vaccine provides an acceptable vac-
cine for evaluation in severely immunocompro m i s e d
patients. We have completed 2 trials of inactivated varicella
vaccine in HCT recipients. In the first, a single-dose regi-
men of inactivated varicella vaccine was found to induce a
transient boost in T-cell responses but did not result in clin-
ical benefit. When the vaccine was given at 1, 2, and 3
months after HCT, we observed enhanced cell-mediated
immunity and decreased severity of herpes zoster in a popu-
lation including autologous and allogeneic transplant recipi-
ents (Figure 7). Patients in the vaccine group developed
VZV reactivation but had minimal cutaneous disease and no
persistent postherpetic neuralgia. With re g a rd to re c o v e ry
of cytokine responses, IFN-γ production was associated with
the re c o v e ry of VZV-specific T-cell proliferation and
i n c reased with time after transplantation. Interleukin-10
p roduction was also observed consistently after HCT and
was highest in patients whose T-cell proliferation response
was restored. The experience with the 3-dose regimen fur-
ther supports the significance of VZV-specific T-cell immu-
nity in maintaining the equilibrium between the latent virus
and host. Our current study is designed to assess whether
earlier VZV immune reconstitution in HCT recipients can
be achieved by immunizing recipients before as well as after
transplantation. 
VZV RESEARCH AND CLINICAL OBSERVATIONS
Of importance is the relationship between studies of
VZV pathogenesis and immunity and observations about the
clinical syndromes associated with VZV reactivation after
H C T. Clinical experience demonstrates that the immuno-
logic impairment experienced by HCT recipients results in
an attack rate of 13% to 55% for symptomatic VZV re a c t i-
vation during the first year [3,29-37] (Table). In contrast, the
annual incidence of herpes zoster among healthy adults is
0.5% [1]. Although the precise viral mechanisms that trigger
reactivation are not known, clinical observations document
that the diff e rences between patterns of VZV and HSV
interactions with dorsal root ganglia cells during latency are
associated with a longer interval to VZV re a c t i v a t i o n
[4,35,36]. HSV-1 disease typically occurs about 2 to 3 weeks
after HCT, whereas VZV re c u rrences present at a median of
5 months. Most VZV re c u rrences appear 2 to 10 months
after transplantation, although some cases are diagnosed as
early as week 1. Analyses of risk factors such as allogeneic
versus autologous transplant, graft-versus-host disease
(GVHD), underlying disease, and pre-BMT irradiation are
equivocal in establishing definitive associations. The patient’s
underlying disease does not appear to influence VZV re a c t i-
vation, but in 1 study, a history of symptomatic herpes zoster
b e f o re transplantation in Hodgkin’s disease patients was
associated with a higher risk of early herpes zoster after
autologous HCT [31]. This observation suggests that
re-establishment of latency may be incomplete in the context
of continued or increased immunosuppression. 
L o c a l i z ed Herpes Zoster
A dermatomal rash is the most common clinical pre s e n t a-
tion of VZV infection in HCT recipients who are sero p o s i t i v e
at the time of transplant, accounting for 85% of cases in 231
HCT recipients in the study by Locksley et al. [3]. The rash of
localized herpes zoster is usually preceded by pain and paras-
thesias in the involved dermatome [1,34,47]. These symptoms
a re undoubtedly a manifestation of viral replication that occurs
in the sensory ganglia and may begin many days before the
cutaneous rash appears. In some cases, the pain syndrome is
not followed by the typical zoster rash, but subsequent
enhanced immune responses suggest a recent VZV re a c t i v a-
tion; this syndrome is re f e rred to as “zoster sine herpete” [48].
F i g u r e 7. T-cell proliferation to varicella-zoster antigen in bone marrow
transplant recipients participating in the study of the 3-dose regimen of inacti-
vated varicella vaccine. The mean stimulation index (SI) ± SE to varicella-
zoster antigen in vaccine recipients tested immediately before immunization at 1
month after transplantation and at 2, 3, 4, 5, and 12 months (j) and responses
of unvaccinated patients at the same time intervals after HCT (u). *Time
points with a statistically significant (P < .05) difference in mean SI between
vaccinated and unvaccinated patients. Reproduced with permission [37].
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The dermatomal distribution of the cutaneous lesions of local-
ized herpes zoster re flects the persistence of VZV in dorsal
root ganglia and its transport down neuronal axons in the
course of reactivation. The rash consists of clusters of vari-
cella-like vesicles in 1 or several sites anteriorly and posteriorly
within the dermatome. Having been delivered to cutaneous
epithelial cells via neuronal pathways, the virus is able to
s p read from cell to cell within the epidermis and dermis, as
evident from the fact that discrete vesicles typically enlarge to
f o rm confluent lesions [47]. Delayed or inadequate host
responses result in an average time for cessation of new
lesion formation of 8 days, compared with 3 to 5 days in the
n o rmal host; the time to complete healing is also pro l o n g e d .
Some HCT patients may have a chronic cutaneous re a c t i v a-
tion of VZV that persists for months, indicating continued
viral replication in ganglia and skin that is unchecked by the
host response [34]. Bacterial superinfection and local scarr i n g
a re also common in HCT recipients with herpes zoster, occur-
ring with an incidence of 17% and 19%, re s p e c t i v e l y.
F a i l u re of the host response to overcome the immune
evasion mechanisms of the virus and stop replication results
in particular complications when VZV reactivation involves
cranial nerves. Corneal damage, facial scarring, facial palsy,
and hearing loss with vestibular symptoms are common
[3,29-36]. Oral lesions of the palate may develop without
any cutaneous lesions when the second branch of cranial
n e rve V is affected. Herpes zoster involving cranial nerv e s
can also be associated with the serious central nervous sys-
tem complication re f e rred to as cerebral angiitis, a syn-
d rome of cerebral vascular inflammation with thro m b o s i s
and micro i n f a rcts. Cerebral angiitis can result in extensive
thrombosis with contralateral hemiparesis [49]. The patho-
logic changes are granulomatous inflammation of the arter-
ial wall, mononuclear cell infiltrates, and vascular necro s i s
associated with the detection of VZV in endothelial cells
and smooth muscle cells of the affected arteries. In some
cases, VZV replication can extend from the dorsal ganglia to
involve the anterior horn cells of the spinal cord, with asso-
ciated abnormalities evident by magnetic resonance imag-
ing. Under these circumstances, inflammation and necrosis
may produce permanent motor deficits [50].
Postherpetic neuralgia (PHN) is the most common com-
plication of herpes zoster in immunocompetent as well as
i m m u n o c o m p romised patients. Postherpetic pain is described
as any pain that persists after resolution of the rash or, alter-
n a t i v e l y, only pain that persists more than 2 months after
cutaneous healing. As a result, estimates of the incidence of
postherpetic neuralgia depend on the definition used. HCT
recipients appear to be at higher risk of PHN. Locksley et al.
[3] observed PHN in 25% of HCT recipients, compare d
with an expected incidence of about 9% in healthy individu-
als; Koc et al. observed PHN and peripheral neuropathy in
68% of HCT patients [37]. 
Cutaneous and Visceral Dissemination
Heightened susceptibility to viral dissemination is fur-
ther evidence of the impact of diminished immunity on the
pathogenesis of VZV infections after HCT. When options
for antiviral therapy were limited, 21% of HCT recipients
with recurrent VZV had visceral dissemination of the virus
and 12% died from complications of re c u rrent VZV [3].
The current risk of morbidity and mortality caused by VZV
infection cannot be compared with the original analyses of
VZV-related disease after BMT, because antiviral therapy is
now available. Nevertheless, more recent studies document
a high risk of cutaneous dissemination (15%-23%) and vis-
ceral involvement (5%-14%) in HCT recipients. For exam-
ple, Schuchter et al. [31] found that 15% of autologous
BMT recipients had cutaneous dissemination, 5% had vis-
ceral dissemination, and 25% had neurologic sequelae,
including PHN. 
Because it is a sign that VZV has infected circulating 
T cells, cutaneous dissemination provides a marker for risk of
visceral dissemination. However, visceral dissemination also
occurs in patients whose cutaneous lesions are localized to the
p r i m a ry dermatome. In addition, some patients have no pri-
m a ry dermatomal involvement but present with diffuse VZV
lesions resembling varicella. This syndrome, re f e rred to as
atypical nonlocalized zoster, accounted for 21% of re c u rre n t
VZV episodes in 1 series of HCT recipients [32]. 
When virus-infected T cells have entered the circ u l a t i o n ,
the virus can reach many visceral organs. The most common
sites for further viral infection are the lungs and liver, re s u l t-
ing in VZV pneumonia, hepatitis, and intravascular coagu-
l o p a t h y. Fatal VZV infections are most often due to viral
pneumonia [51]. The risk of VZV dissemination is incre a s e d
Incidence of Varicella-Zoster Virus (VZV) Infections After HCT
Clinical Presentation
VZV Localized Atypical
Year Reference Underlying Disease Transplant Type n Infection (%) Zoster (%) Zoster (%) Varicella (%)
1980 [8] Leukemia Allogeneic/syngeneic 33 21 — — —
1982 [10] Leukemia/aplastic anemia Allogeneic/syngeneic 98 52 — — —
1985 [1] Leukemia/aplastic anemia Allogeneic 1394 17 85 15 0
1986 [11] Hematological malignancy Allogeneic 73 36 91 7 2
1989 [7]* Leukemia/solid tumors Autologous 236 23 75 13 18
1989 [12] Leukemia/lymphoma Autologous 153 28 77 20 2
1991 [13] Hodgkin’s disease Autologous 28 32 100 0 0
1992 [36] Leukemia/lymphoma/other Autologous/allogeneic 51 31 100 0 0
2000 [38] Leukemia/lymphoma/other Allogeneic 100 41 80 20 † —
*This study evaluated pediatric patients only. 
†17% had varicella-like cutaneous involvement and 3% had visceral dissemination.
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in patients with acute GVHD, and VZV has also been identi-
fied as a cause of late interstitial pneumonia in HCT patients
with chronic GVHD [52]. Some HCT recipients pre s e n t
with signs of visceral dissemination 24 to 96 hours before the
d e rmatomal rash becomes evident [53-57]. The fact that vis-
ceral dissemination has been observed in HCT patients with-
out any signs of cutaneous disease demonstrates that cell-
associated viremia can occur without replication of the viru s
in skin, presumably by entry of virus into T cells that traffic
t h rough sensory ganglia [3]. Immunosuppression also pre d i s-
poses to CNS infection, which manifests clinically as menin-
goencephalitis, during VZV reactivation [58]. Visceral dis-
semination increases the mortality of VZV re a c t i v at i o n
s u b s t a n t i a l l y, from 7% to 55%. Mortality is usually due to
pneumonia, but the risk of fatal infection is highest among
patients who develop both pneumonia and encephalitis. 
Second Episodes of Herpes Zoster
Some HCT recipients have recurrences of herpes zoster
within days after antiviral therapy is stopped, indicating the
failure to reestablish latency in the short term. When zoster
has resolved, however, second episodes are unusual. Only
2% of patients in 1 large series had 2 episodes of herpes
zoster, occurring an average of 25 months (range 4-41) after
transplantation [3]. These data confirm the importance of
reconstituted VZV immunity in maintaining latency. 
IMPLICATIONS FOR THE MANAGEMENT OF VZV
INFECTIONS IN HCT RECIPIENTS
D i ag n o s i s
The unusual clinical manifestations of re c u rrent VZV
in HCT recipients re q u i re a high index of suspicion for
VZV as a potential etiology. Reliance on rapid, sensitive
methods for laboratory diagnosis is essential in many cases.
These methods include direct immunofluore s c e n c e ,
enzyme immunoassay, and PCR, as well as more rapid and
sensitive viral culture methods such as shell vial assays [59].
S e rologic approaches to the diagnosis of acute VZV re a c t i-
vation are not reliable because VZV IgG antibodies are
p resent in all latently infected individuals, VZV IgM assays
a re difficult to standardize, intermittent detection of IgM
antibodies is re p o rted in individuals with no evidence of
reactivation, and some patients have herpes zoster without
eliciting IgM antibodies. 
Antiviral Tr e a t m e n t
Acyclovir has been shown to be effective for the tre a t-
ment of re c u rrent VZV infection in immunocompro m i s e d
patients in placebo-controlled trials and extensive clinical
experience [47]. Antiviral treatment compensates for the
delayed host response and results in shorter time to cessation
of new lesion formation, more rapid crusting and healing,
and prevention of cutaneous and visceral dissemination. Acy-
clovir therapy initiated within 72 hours after the onset of
VZV reactivation can be expected to reduce the duration of
new lesion formation in HCT patients to approximately 3
days. On average, early antiviral treatment should cause the
cessation of acute pain within 4 days, crusting of lesions by 7
days, and complete healing by 2 to 3 weeks. Although early
acyclovir treatment is likely to produce the best results, clini-
cal benefit can still occur when therapy is delayed for more
than 3 days [60]. In 1 series, none of 29 immunocompro-
mised patients whose therapy was initiated more than 3 days
after the onset of the rash had pro g ressive herpes zoster,
c o m p a red with 3 of 17 patients in the placebo gro u p .
Although the drug eliminates the life-threatening compli-
cations of VZV reactivation in most patients, relapse of her-
pes zoster is a clinical problem in some HCT patients who
a re treated with acyclovir. In 1 series, 5 of 40 patients (12%)
developed new lesions; in 3 of the 5 patients, relapse occurre d
less than 4 days after treatment was stopped [61]. Early acy-
clovir therapy may delay the re c o v e ry of VZV- s p e c i fic immu-
nity in some patients. Nevertheless, most patients respond to
t reatment with a second course of acyclovir.
Although acyclovir is clearly beneficial for the treatment
of acute herpes zoster, its effect on the incidence of PHN
has been more difficult to establish. Among HCT re c i p i-
ents, 9 of 40 (20%) patients had recurrence of pain after ces-
sation of therapy [62].
The efficacy of oral acyclovir for herpes zoster in HCT
patients has not been firmly established, and its bioavailabil-
ity is low. The oral route of administration is appropriate for
patients who are carefully selected based on their presenta-
tion with localized herpes zoster only, at longer interv a l s
after HCT. Acyclovir has been shown to be a safe agent in
m o re than a decade of clinical experience and is tolerated
well by HCT patients, although side effects are more fre-
quent than in other populations. In 1 series, nausea and
vomiting, which is particularly associated with elevated crea-
tinine, occurred in 40% of treated patients [61]. Nephro-
toxic effects, defined as a 50% rise in serum creatinine, were
also more common than in other patient populations; 10%
to 25% of HCT patients receiving acyclovir were reported
to have abnormal serum creatinine, but these elevations may
have been caused by other medications given concurrently.
Because acyclovir is excreted by glomerular filtration, other
d rugs that affect renal function, such as cyclosporine, can
increase plasma drug concentrations. Acyclovir dosage must
be adjusted in relation to creatinine clearance. Acute neuro-
toxicity associated with acyclovir treatment has been
reported in patients with impaired renal clearance. In most
instances, abnormal liver function tests in patients with
VZV reactivation are likely to indicate viral hepatitis, not
drug toxicity. Acyclovir does not have hematologic toxicity
and does not interfere with engraftment in HCT recipients.
Valaciclovir and famciclovir are nucleoside analogs that
resemble acyclovir in their stru c t u re and mechanisms of
action; all 3 drugs interf e re with viral thymidine kinase
activity [63,64]. Valaciclovir and famciclovir are absorbed
much more effectively after oral administration than acy-
clovir and have a comparable safety profile. Although con-
trolled trials to establish their clinical efficacy have not been
done in HCT patients, valaciclovir and famciclovir are use-
ful alternatives to acyclovir in those patients with herpes
zoster for whom oral therapy is considered appro p r i a t e .
They require only 3 doses per day but are more expensive
than acyclovir and do not have significantly enhanced effi-
cacy compared with the recommended dosage of oral acy-
clovir in otherwise healthy individuals. 
VZV resistance to acyclovir has not been common in HCT
recipients, but it has been re p o rted in patients with acquire d
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i m m u n o d e ficiency syndrome [65]. When VZV re a c t i v a t i o n
occurs in HCT recipients, it may resolve slowly or recur short l y
after antiviral therapy is stopped. In most cases, this clinical pat-
t e rn is related to limitations in the host response, for which the
d rug compensates only part i a l l y, and does not re p resent the
e m e rgence of acyclovir resistance. Because most resistant VZV
strains have mutations in thymidine kinase, acyclovir, valaci-
c l o v i r, and famciclovir are all equally ineffective [47,65,66]. Fos-
c a rnet has antiviral activity against VZV strains that are not
inhibited by acyclovir, but its clinical use is complicated by
potential liver toxicity and emergence of resistance [67]. In
some cases, acyclovir- resistant VZV strains emerge during ther-
a p y, a risk that is associated particularly with prolonged, low-
dose regimens, but VZV isolates from later re c u rrences may
have re c o v e red susceptibility to acyclovir. Ganciclovir and acy-
clovir have equivalent antiviral activity against VZV in vitro ,
but ganciclovir efficacy has not been evaluated in patients with
herpes zoster because it is more toxic than the primary dru g s .
Based on in vitro analysis, ganciclovir given to CMV- i n f e c t e d
HCT recipients might ameliorate concurrent VZV infection.
Koc et al. [37] found that patients receiving ganciclovir had
delayed onset of VZV reactivation until after 4 months.
Although the live attenuated varicella vaccine is not
indicated for administration after HCT, some children who
have received this vaccine may become transplant recipients.
The risk is significantly less than naturally acquired VZV
infection, but the vaccine virus can establish latency and
reactivation may occur [68]. Because the vaccine is prepared
from the Oka strain of VZV, which retains susceptibility to
acyclovir and related antiviral agents, vaccine-related herpes
zoster can be treated with acyclovir. 
Varicella-Zoster Imm u n og l o b u l i n
Varicella-zoster immunoglobulin (VZIG) contains high
titers of VZV IgG and is indicated for immediate postexpo-
s u re prophylaxis of high-risk patients who have not had VZV
infection and have close contact with varicella or herpes
z o s t e r. VZIG is not used in patients with herpes zoster,
because VZV IgG titers are maintained despite the loss of
cell-mediated immunity to the virus. There is no indication
that passive antibody prophylaxis increases existing antibody
titers or reduces the risk of VZV reactivation after HCT [38].
The clinical experience is that HCT recipients exposed to
varicella or herpes zoster are rarely reinfected with the viru s ,
even when no VZV- s p e c i fic T-cell responses are detectable.
The persistence of VZV IgG may protect against exogenous
re e x p o s u res to the virus, by neutralization or other antibody-
mediated mechanisms, even though antibodies fail to block
reactivation of the patient’s endogenous virus. 
Antiviral Pr o p hy l a x i s
Although daily acyclovir prophylaxis inhibits the reacti-
vation of VZV, antiviral drugs are not usually given to HCT
recipients for VZV suppression. Herpes zoster, especially
when it occurs shortly after HCT, may cause disseminated
disease; however, prompt initiation of acyclovir therapy,
given when symptoms of VZV reactivation appear, is an
effective alternative to continued administration of antiviral
drugs. In 2 studies of acyclovir prophylaxis after HCT, VZV
reactivation was managed effectively among placebo subjects
who were given intravenous acyclovir at the onset of symp-
toms [69-71]. Giving antiviral agents daily at the low doses
used for prophylaxis may facilitate the selection of VZV
strains that are thymidine kinase–negative and there f o re
resistant. In addition, the cumulative attack rate for VZV
reactivation in treated and placebo patients was equivalent
over a 1-year time period, indicating that suppre s s i o n
required a constant presence of the drug in tissues. 
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